Jazz Pharmaceuticals (JAZZ) FY2023 results: revenue $3.8 billion, up 4.8% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $3.8 billion for fiscal 2023, the year ended 31 December 2023, up 4.8% on the year before. Net income was $415 million, and diluted earnings per share $6.10. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2024.
Revenue
$3.8 billion
+4.8% on the year
FY2016FY2023
Operating margin
15.1%
-1.8% a year earlier
FY2016FY2023
Net income
$415 million
FY2016FY2023
Diluted EPS
$6.10
FY2016FY2023
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Operating cash flow
1,092
1,272
779
-14.1%
Capital expenditure
24.0
29.0
27.6
-17.5%
Free cash flow
1,068
1,243
751
-14.1%
Free cash flow margin
27.9%
34.0%
24.3%
Cash from investing
-163
-446
-5,212
Cash from financing
-305
-529
3,971
Depreciation and amortisation
30.4
30.3
26.7
+0.3%
Share-based compensation
227
222
189
+2.2%
Buybacks
270
0.1
0.0
+499,457.4%
Diluted shares, weighted
72m
63m
60m
+15.2%
Shares outstanding at period end
62m
63m
62m
-1.5%
Balance sheet
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Shareholders' equity
3,737
3,086
3,965
+21.1%
Debt
5,713
5,724
6,050
-0.2%
Operating lease liabilities
59.2
71.8
87.2
-17.6%
Finance lease liabilities
5.0
5.2
6.3
-3.3%
Other liabilities
1,879
1,948
2,190
-3.5%
Total liabilities and equity
11,393
10,835
12,299
+5.2%
Goodwill
1,753
1,693
1,828
+3.6%
Intangible assets
5,418
5,794
7,152
-6.5%
Securities held for sale or to maturity
1,626
881
591
+84.5%
Cash and equivalents
1,506
881
591
+70.9%
Receivables
706
651
563
+8.3%
Inventory
597
714
1,073
-16.4%
Other assets
n/a
220
500
Total assets
11,393
10,835
12,299
+5.2%
10-K for the year ended 31 December 2023, filed 28 February 2024: the filing.